Integrative medicine considerations for convalescence from mild-to-moderate COVID-19 disease

被引:15
|
作者
Alschuler, Lise [1 ,2 ]
Chiasson, Ann Marie [1 ,2 ]
Horwitz, Randy [1 ,2 ]
Sternberg, Esther [1 ,2 ]
Crocker, Robert [1 ,2 ]
Weil, Andrew [2 ,3 ]
Maizes, Victoria [1 ,2 ]
机构
[1] Univ Arizona, Coll Med, Tucson, AZ 85721 USA
[2] Andrew Weil Ctr Integrat Med, Tucson, AZ 85711 USA
[3] Univ Arizona, Tucson, AZ 85721 USA
关键词
Integrative medicine; COVID-19; Immune; Diet; Supplements; Osteopathic manipulation; Qigong; Exercise; Stress reduction; Creative expression; Aromatherapy; RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; FUNCTIONAL RECEPTOR; PHYSICAL HEALTH; IMMUNE FUNCTION; LUNG-FUNCTION; DOUBLE-BLIND; EXERCISE; QIGONG; SLEEP;
D O I
10.1016/j.explore.2020.12.005
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
The majority of individuals infected with SARS-CoV-2 have mild-to-moderate COVID-19 disease. Convalescence from mild-to-moderate (MtoM) COVID-19 disease may be supported by integrative medicine strategies. Integrative Medicine (IM) is defined as healing-oriented medicine that takes account of the whole person, including all aspects of lifestyle. Integrative medicine strategies that may support recovery from MtoM COVID-19 are proposed given their clinically studied effects in related conditions. Adoption of an antiinflammatory diet, supplementation with vitamin D, glutathione, melatonin, Cordyceps, Astragalus and garlic have potential utility. Osteopathic manipulation, Qigong, breathing exercises and aerobic exercise may support pulmonary recovery. Stress reduction, environmental optimization, creative expression and aromatherapy can provide healing support and minimize enduring trauma. These modalities would benefit from clinical trials in people recovering from COVID-19 infection. (c) 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
引用
收藏
页码:140 / 148
页数:9
相关论文
共 50 条
  • [31] A Randomized Placebo-Controlled Trial of Leronlimab in Mild-To-Moderate COVID-19
    Seethamraju, Harish
    Yang, Otto O.
    Loftus, Richard
    Ogbuagu, Onyema
    Sammartino, Daniel
    Mansour, Ali
    Sacha, Jonah B.
    Ojha, Sohita
    Hansen, Scott G.
    Arman, Arvin Cyrus
    Lalezari, Jacob P.
    CLINICAL THERAPEUTICS, 2024, 46 (11) : 891 - 899
  • [32] The efficacy of neutralizing monoclonal antibodies in transplant recipients with mild-to-moderate COVID-19
    Arimura, Ken
    Tagaya, Etsuko
    Kikuchi, Ken
    Mitsuda, Toshihiro
    Ebihara, Fumiya
    Maruyama, Takumi
    Hamada, Yukihiro
    Unagami, Kohei
    Kanzawa, Taichi
    Sekiguchi, Haruki
    Shimamoto, Ken
    Ishida, Hideki
    Egawa, Hiroto
    Tanaka, Junji
    Kawana, Masatoshi
    TRANSPLANT IMMUNOLOGY, 2023, 77
  • [33] Clinical and subclinical acute kidney injury in children with mild-to-moderate COVID-19
    Saygili, Seha
    Canpolat, Nur
    Cicek, Rumeysa Yasemin
    Agbas, Ayse
    Yilmaz, Esra Karabag
    Sakalli, Ayse Ayzit Kilinc
    Aygun, Deniz
    Akkoc, Gulsen
    Demirbas, Kaan Can
    Konukoglu, Dildar
    Cokugras, Haluk
    Caliskan, Salim
    Sever, Lale
    PEDIATRIC RESEARCH, 2023, 93 (03) : 654 - 660
  • [34] Monoclonal antibodies for mild-to-moderate COVID-19 in multiple sclerosis: A case series
    Moccia, Marcello
    Buonomo, Antonio Riccardo
    Scotto, Riccardo
    Viceconte, Giulio
    Nobile, Mariano
    Lanzillo, Roberta
    Morra, Vincenzo Brescia
    Gentile, Ivan
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2022, 439
  • [35] Clinical Pathways When Considering Antimicrobials for the Treatment of Mild-to-Moderate COVID-19
    Krauth, Daniel S.
    MILITARY MEDICINE, 2022, 187 (7-8) : 186 - 188
  • [36] Mild-to-moderate COVID-19 may affect nervous system function in convalescents
    Lulek, M.
    Malecka-Gieldowska, M.
    Ciepiela, O.
    CLINICA CHIMICA ACTA, 2024, 558 : 2 - 3
  • [37] A randomized phase 2 study on demeclocycline in patients with mild-to-moderate COVID-19
    Iwahori, Kota
    Nii, Takuro
    Yamaguchi, Norihiko
    Kawasaki, Takahiro
    Okamura, Satomi
    Hashimoto, Kazuki
    Matsuki, Takanori
    Tsujino, Kazuyuki
    Miki, Keisuke
    Osa, Akio
    Goya, Sho
    Abe, Kinya
    Mori, Masahide
    Takeda, Yoshito
    Yamada, Tomomi
    Kida, Hiroshi
    Kumanogoh, Atsushi
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [38] Prognostic factors of disease progression in patients with mild-to-moderate COVID-19 on early remdesivir treatment in Taiwan
    Ho, Yu-Chien
    Chang, Min-Chi
    Lin, Wen-Ying
    Wu, Chia-Ying
    Liu, Szu-Yu
    Chuang, Chien
    Juan, Chih-Han
    Liu, Chia-Jen
    Lin, Yi-Tsung
    JOURNAL OF INFECTION AND PUBLIC HEALTH, 2025, 18 (05)
  • [39] Favipiravir in Patients With Early Mild-to-moderate Coronavirus Disease 2019 (COVID-19): A Randomized Controlled Trial
    Golan, Yoav
    Campos, Jesus Abraham Simon
    Woolson, Rob
    Cilla, Donald
    Hanabergh, Rodolfo
    Gonzales-Rojas, Yaneicy
    Lopez, Reynaldo
    Finberg, Robert
    Balboni, Armand
    CLINICAL INFECTIOUS DISEASES, 2023, 76 (03) : E10 - E17
  • [40] Thyroid dysfunction as a long-term post-COVID-19 complication in mild-to-moderate COVID-19
    Yanachkova, Vesselina
    Stankova, Teodora
    Staynova, Radiana
    BIOTECHNOLOGY & BIOTECHNOLOGICAL EQUIPMENT, 2023, 37 (01) : 194 - 202